Tag: 2016

  • Oliver Dowden – 2016 Parliamentary Question to the Department of Health

    Oliver Dowden – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Oliver Dowden on 2016-02-29.

    To ask the Secretary of State for Health, what steps his Department is taking to ensure that information relating to infertility and its treatment is available to those affected.

    Jane Ellison

    The Human Fertilisation and Embryology Authority have a statutory duty to publish information for patients and donors about fertility treatment and the clinics that it licenses. The Authority is currently reviewing the information published on its website following extensive research and is working with NHS Choices to make sure that all patients are directed to the right information at the right time.

    Individuals with fertility problems can discuss these issues with their general practitioners and ask to be referred to a fertility specialist to discuss the difficulties that they are having in conceiving and the options that are open to them.

  • Tim Loughton – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    Tim Loughton – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    The below Parliamentary question was asked by Tim Loughton on 2016-03-24.

    To ask the Secretary of State for Foreign and Commonwealth Affairs, which cases of human rights violations against Tibetans he or ministerial colleagues have taken up with their Chinese counterparts in each of the last three years.

    Mr Hugo Swire

    Over the course of the UK-China Human Rights Dialogues held in Beijing in April 2015 and in London in 2014, senior officials raised the cases of 22 Tibetans detained by the Chinese authorities. We also raised the full range of our wider human rights concerns on Tibet at each of these rounds, including allegations of torture, freedom of expression, right to a fair trial and freedom of religion or belief. A round of the Human Rights Dialogue was not held in 2013.

  • Tulip Siddiq – 2016 Parliamentary Question to the HM Treasury

    Tulip Siddiq – 2016 Parliamentary Question to the HM Treasury

    The below Parliamentary question was asked by Tulip Siddiq on 2016-05-04.

    To ask Mr Chancellor of the Exchequer, with reference to his Department’s news story of 10 April 2016, UK launches cross-government taskforce on the Panama Papers, how many full-time equivalent staff from each agency have been allocated to that taskforce; and whether any staff in that taskforce (a) have the power of arrest, (b) are authorised to access directly the contents of Suspicious Activity Reports, (c) are able to request data on companies incorporated in foreign countries and (d) have powers to fully investigate any allegations of (i) non-compliance with sanctions, (ii) money laundering and (iii) terrorist financing.

    Mr David Gauke

    There are upward of 100 people currently involved in the multi-agency Taskforce. The number of officers holding each different power is not recorded centrally. Each taskforce member agency has its own statutory powers, networks, functions and confidentiality restrictions. By drawing on these powers and networks, the taskforce will be more effective than any single agency acting independently.

  • Crispin Blunt – 2016 Parliamentary Question to the Department of Health

    Crispin Blunt – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Crispin Blunt on 2016-06-09.

    To ask the Secretary of State for Health, with reference to paragraph 10 of NHS England’s Strategic Framework for Specialised Services board paper, published in May 2016, what plans NHS England has to trial alternative reimbursement models for drugs and devices.

    George Freeman

    As set out in the NHS England Board Paper, improving the adoption of new technologies and treatments will be an important element of NHS England’s strategic framework for specialised services. As part of the work to develop that framework, NHS England will be working with a range of stakeholders to explore how alternative reimbursement models could be deployed, including in the context of the recommendations of the Accelerated Access Review due for publication this summer.

  • Diana Johnson – 2016 Parliamentary Question to the Department for Business, Energy and Industrial Strategy

    Diana Johnson – 2016 Parliamentary Question to the Department for Business, Energy and Industrial Strategy

    The below Parliamentary question was asked by Diana Johnson on 2016-09-06.

    To ask the Secretary of State for Business, Energy and Industrial Strategy, what his policy is on future collaboration with the EU on consumer protections in relation to e-commerce; if he will make it his policy to ensure UK consumers who access e-commerce firms located in the EU single market continue to be offered the protections currently provided by the Directive on Consumer Rights of 25 October 2011 (2011/83/EC).

    Margot James

    We are yet to begin our negotiations to withdraw from the European Union and it would be wrong to set out unilateral positions in advance. At every step of these negotiations we will work to ensure the best possible outcome for the UK.

  • Ronnie Cowan – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    Ronnie Cowan – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    The below Parliamentary question was asked by Ronnie Cowan on 2016-10-21.

    To ask the Secretary of State for Foreign and Commonwealth Affairs, what role he expects the UK to play in discussions at the UN General Assembly on multilateral nuclear disarmament; and if he will make a statement.

    Sir Alan Duncan

    The UK plays a full and active role in the UN First Committee on disarmament and international security. We are considering nearly 70 resolutions covering the whole spectrum of First Committee activity working with other States to prevent proliferation and to make progress towards multilateral nuclear disarmament.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-13.

    To ask Her Majesty’s Government what information (1) the National Cancer Intelligence Network, (2) Public Health England, (3) the National Institute for Health Research, and (4) the NHS more broadly, hold on mesothelioma and other less common cancers covering (a) hospital surgical volumes; (b) hospital systemic anti-cancer treatment volumes; (c) hospital radiotherapy volumes; (d) clinical trial volumes by hospital; (e) cancer stage and grade at presentation; (f) short-term patient outcomes; (g) one-year survival rates; and (h) five-year survival rates.

    Lord Prior of Brampton

    The National Cancer Registration Service and National Cancer Intelligence Network are both part of Public Health England and collect data on all diagnoses of cancer in England, including mesothelioma and other rare cancers.

    Data on one-year survival from mesothelioma have been published and is attached. The relative survival for men at one year was 34%; varying between 27% and 39% across England. The relative survival for women at one year was 40%; varying between 24% and 70% across England.

    Data on hospital surgical volumes; hospital systemic anti-cancer treatment volumes; hospital radiotherapy volumes; clinical trial volumes by hospital; cancer stage and grade at presentation; short-term patient outcomes; and five-year survival rates are not held in the format requested.

    Data on whether patients have been offered/entered into a clinical trial is now mandated as part of the Cancer Outcomes and Services Dataset, so we anticipate being able to report on this in the future.

    Within the current financial year, the National Institute for Health Research (NIHR) Clinical Research Network has recruited up to 80 trials in less common cancers in a total of 124 recruitment sites. Details of the trials recruiting at each site are in the attached table, Trials in less common cancers in portfolio of NIHR Clinical Research Network. The NIHR does not collect information on hospital surgical volumes; hospital systemic anti-cancer treatment volumes; hospital radiotherapy volumes; cancer stage and grade at presentation; short-term patient outcomes; one-year survival rates; and five-year survival rates.

    With regard to National Health Service more broadly, NHS England has advised that it does not hold the information requested.

  • Jamie Reed – 2016 Parliamentary Question to the Department for Energy and Climate Change

    Jamie Reed – 2016 Parliamentary Question to the Department for Energy and Climate Change

    The below Parliamentary question was asked by Jamie Reed on 2016-02-08.

    To ask the Secretary of State for Energy and Climate Change, what estimate she has made of the amount of energy that would be generated in West Cumbria as a result of the (a) Moorside Nuclear development and (b) Solway Firth Tidal Gateway project; and what proportion of UK energy would be generated by those projects.

    Andrea Leadsom

    Nugen’s proposal for Moorside is for three Toshiba Westinghouse AP1000 reactors, which together have a stated generation capacity of 3.6GW. This is equivalent to around 27 TWh per year once the station is fully operational. This is estimated to be equivalent to around 7% of the UK’s electricity generation needs in 2030.

    No assessment of the amount of generation which could be produced by a potential Solway Firth Tidal Gateway project has been made by my Department as we have not received any detailed proposal for such a project.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-02-29.

    To ask the Secretary of State for Health, what the total cost of treating liver disease was in (a) England and (b) each parliamentary constituency in the last year for which figures are available.

    Jane Ellison

    Information on the total cost of treating liver disease in England and in each parliamentary constituency is not available centrally.

    Such information as is available is from reference costs, which are the average unit cost to National Health Service hospital trusts of providing defined services to patients in a given financial year. Reference costs for acute care are collected by Healthcare Resource Group (HRG), which are standard groupings of similar treatments that use similar resources. HRGs are organised by chapters and sub-chapters, representing different body systems, and HRG sub-chapter GC describes hepatobiliary and pancreatic system disorders. The total costs in the following table, calculated from the national average unit costs and activity submitted in reference costs, will therefore include the costs to NHS hospitals of treating liver and liver related diseases, but also the costs of other related disorders.

    Estimated total costs (£ millions) to NHS hospitals of treating hepatobiliary and pancreatic system disorders, 2014-15

    Liver failure disorders

    £17.7 million

    Malignant, hepatobiliary or pancreatic disorders

    £54.3 million

    Non-malignant, hepatobiliary or pancreatic disorders

    £328.1 million

    Total costs

    £400.0 million

    Source: reference costs, Department of Health

    Notes:

    1. The following HRGs are included in the table:

    Liver Failure Disorders with Multiple Interventions

    Liver Failure Disorders with Single Intervention

    Liver Failure Disorders without Interventions, with CC (Complication and Comorbidity) Score 5+

    Liver Failure Disorders without Interventions, with CC Score 0-4

    Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions

    Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 5+

    Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 2-4

    Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-1

    Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 6+

    Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 3-5

    Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 1-2

    Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 9+

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 4-8

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 0-3

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 9+

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 4-8

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-3

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 8+

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 5-7

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 2-4

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0-1

    1. These HRGs are common groupings of the International Classification of Disease (ICD-10) codes used to count the number of finished admission episodes with a primary or secondary diagnosis of liver disease or liver related disease. They also include other ICD-10 codes.

    “

  • Luciana Berger – 2016 Parliamentary Question to the Department of Health

    Luciana Berger – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Luciana Berger on 2016-03-24.

    To ask the Secretary of State for Health, pursuant to the Answer of 18 January 2016 to Question 22159, on mental illness and A&E departments, if he will publish that data for each month of 2015 and 2016.

    Alistair Burt

    There are no plans to routinely publish the number of accident and emergency attendances with a duration to departure of more than four hours, for patients with a primary diagnosis of psychosis, by age group.